CP-461 for the Treatment of Crohn's Disease
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00042055. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Pilot Study of CP-461 in the Treatment of Moderately to Severely Active Crohn's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients with moderately to severely active Crohn's disease will be treated with oral CP-461 200 mg (2 x 100 mg capsules) twice-daily for 8 weeks. The purpose of this study is to see if CP-461 improves the symptoms of Crohn's disease and/or the patient's quality of life. Patient's safety will be monitored throughout the study.
Study identification
- NCT ID
- NCT00042055
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2002 (Type not available)
- Primary completion
- Not listed
- Completion
- Sep 2003 (Actual)
- Last update posted
- Oct 17, 2011
2002 – 2003
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Drug Research | Birmingham | Alabama | 35211 | — |
| Community Clinical Trials | Orange | California | 92868 | — |
| Florida Medical Research Institute, PA | Gainesville | Florida | 32607 | — |
| Atlanta Gastroenterology Associates | Atlanta | Georgia | 30342 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Indianapolis Gastroenterology and Hepatology, Inc. | Indianapolis | Indiana | 46237 | — |
| Digestive Disease Associates, PA | Columbia | Maryland | 21044 | — |
| Atlantic Gastroenterology Associates | Egg Harbor | New Jersey | 08234 | — |
| Long Island Clinical Research Associates, LLP | Great Neck | New York | 11021 | — |
| Consultants for Clinical Research, Inc. | Cincinnati | Ohio | 95219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00042055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 17, 2011 · Synced Nov 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.